Individual compoundsCategoriesResearch SetsMembershipJournalSign in
← Journal

Inside the Biology

Randomized Human Trials

Visceral Fat Is Not Just Another Fat Depot

2–25 min read

Two individuals can carry similar quantities of body fat while having meaningfully different metabolic profiles. One reason is where that fat is stored.

Subcutaneous adipose tissue lies beneath the skin. Visceral adipose tissue accumulates around internal organs and is more strongly associated with metabolic dysfunction. This distinction has made visceral adiposity an important research endpoint independent of total body weight.

Tesamorelin provides an unusually useful model for studying it. Tesamorelin is a growth-hormone-releasing hormone analogue investigated extensively in people living with HIV who have abdominal fat accumulation. Unlike exogenous growth hormone, it stimulates endogenous GH secretion and consequently influences the GH/IGF-1 axis.

Randomized human research has demonstrated meaningful reductions in visceral adipose tissue in the specific populations studied. The pivotal randomized, placebo-controlled trial, enrolling 412 participants, reported that visceral adipose tissue decreased by 15.2% in the tesamorelin group over 26 weeks, compared with a 5.0% increase in the placebo group. A pooled analysis of two phase 3 trials with extension data, covering 806 participants, corroborated a significant reduction in visceral fat with continued treatment.

A separate, smaller randomized clinical trial (n=50) specifically investigated effects on both visceral adipose tissue and liver fat, reporting reductions in both compared with placebo over six months.

Research outside HIV-associated lipodystrophy exists but is substantially smaller and less consistent. None of these findings means results can automatically be generalized to healthy populations without HIV-associated fat redistribution.

Instead, tesamorelin research demonstrates something more fundamental: adipose tissue is heterogeneous. Changes in scale weight, total fat mass, subcutaneous fat and visceral fat are not biologically interchangeable outcomes.

Research Status

Substantial randomized human clinical trial literature exists within a specific population (HIV-associated abdominal fat accumulation). Generalization to healthy or other populations has not been established and requires caution.

Selected Research

Related Research